The QIAstat-Dx Respiratory Panel Plus is designed to support clinical decision-making in diagnosing upper respiratory infections and covers 21 viral and bacterial targets. It was previously authorized under a U.S. FDA Emergency Use Authorization (EUA) as the QIAstat-Dx Respiratory SARS-CoV-2 Panel. The panel leverages QIAstat-Dx's ability to quickly amplify many genetic targets at once using real-time PCR technology, delivering results in about one hour and with less than one minute of hands-on time. Cycle threshold (Ct) values and amplification curves are easily viewable and provide healthcare professionals with additional clinical information.
FDA Clears QIAGEN's Qiastat-Dx Respiratory Syndromic Testing Panel For Fast And Accurate Results
Company Profile
Mon. 13 May 2024, 3:22am ET
Benzinga
News